CN110652006A - 一种缓解体力疲劳的组合物及其制备方法 - Google Patents
一种缓解体力疲劳的组合物及其制备方法 Download PDFInfo
- Publication number
- CN110652006A CN110652006A CN201910968586.3A CN201910968586A CN110652006A CN 110652006 A CN110652006 A CN 110652006A CN 201910968586 A CN201910968586 A CN 201910968586A CN 110652006 A CN110652006 A CN 110652006A
- Authority
- CN
- China
- Prior art keywords
- parts
- extract
- physical fatigue
- relieving
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title abstract description 21
- 240000005373 Panax quinquefolius Species 0.000 claims abstract description 46
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 46
- 244000042430 Rhodiola rosea Species 0.000 claims abstract description 46
- 235000003713 Rhodiola rosea Nutrition 0.000 claims abstract description 46
- 235000020696 epimedium extract Nutrition 0.000 claims abstract description 22
- 241001145025 Saussurea involucrata Species 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims abstract description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 48
- 239000003826 tablet Substances 0.000 claims description 44
- 239000000706 filtrate Substances 0.000 claims description 40
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 28
- 239000008187 granular material Substances 0.000 claims description 23
- 239000000843 powder Substances 0.000 claims description 22
- 238000001914 filtration Methods 0.000 claims description 20
- 238000010438 heat treatment Methods 0.000 claims description 20
- 238000010992 reflux Methods 0.000 claims description 18
- 238000002156 mixing Methods 0.000 claims description 15
- 238000007873 sieving Methods 0.000 claims description 15
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 14
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 14
- 229920002472 Starch Polymers 0.000 claims description 14
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 14
- 235000019359 magnesium stearate Nutrition 0.000 claims description 14
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 14
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 14
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 14
- 239000011734 sodium Substances 0.000 claims description 14
- 229910052708 sodium Inorganic materials 0.000 claims description 14
- 239000008107 starch Substances 0.000 claims description 14
- 235000019698 starch Nutrition 0.000 claims description 14
- 239000000463 material Substances 0.000 claims description 12
- 238000001694 spray drying Methods 0.000 claims description 10
- 238000000605 extraction Methods 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000007888 film coating Substances 0.000 claims description 8
- 238000009501 film coating Methods 0.000 claims description 8
- 238000013461 design Methods 0.000 claims description 7
- 238000005469 granulation Methods 0.000 claims description 7
- 230000003179 granulation Effects 0.000 claims description 7
- 239000011248 coating agent Substances 0.000 claims description 6
- 238000000576 coating method Methods 0.000 claims description 6
- 235000013402 health food Nutrition 0.000 claims description 6
- 239000011347 resin Substances 0.000 claims description 6
- 229920005989 resin Polymers 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- 240000002853 Nelumbo nucifera Species 0.000 claims description 5
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims description 5
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 238000001704 evaporation Methods 0.000 claims description 5
- 230000001965 increasing effect Effects 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000008213 purified water Substances 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 239000003463 adsorbent Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 230000008020 evaporation Effects 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 20
- 230000006870 function Effects 0.000 abstract description 12
- 241000282414 Homo sapiens Species 0.000 abstract description 8
- 235000013305 food Nutrition 0.000 abstract description 8
- 239000003814 drug Substances 0.000 abstract description 6
- 210000003734 kidney Anatomy 0.000 abstract description 6
- 210000004556 brain Anatomy 0.000 abstract description 5
- 210000002216 heart Anatomy 0.000 abstract description 5
- 230000036039 immunity Effects 0.000 abstract description 5
- 230000006872 improvement Effects 0.000 abstract description 5
- 210000004072 lung Anatomy 0.000 abstract description 5
- 210000001835 viscera Anatomy 0.000 abstract description 5
- 230000002929 anti-fatigue Effects 0.000 abstract description 4
- 230000017531 blood circulation Effects 0.000 abstract description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 3
- 230000033228 biological regulation Effects 0.000 abstract description 3
- 239000001301 oxygen Substances 0.000 abstract description 3
- 229910052760 oxygen Inorganic materials 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 3
- 108090000623 proteins and genes Proteins 0.000 abstract description 3
- 102000004169 proteins and genes Human genes 0.000 abstract description 3
- 229930003231 vitamin Natural products 0.000 abstract description 3
- 235000013343 vitamin Nutrition 0.000 abstract description 3
- 239000011782 vitamin Substances 0.000 abstract description 3
- 229940088594 vitamin Drugs 0.000 abstract description 3
- 210000003169 central nervous system Anatomy 0.000 abstract description 2
- 230000007423 decrease Effects 0.000 abstract description 2
- 235000020774 essential nutrients Nutrition 0.000 abstract description 2
- 230000005284 excitation Effects 0.000 abstract description 2
- 230000005764 inhibitory process Effects 0.000 abstract description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 abstract description 2
- 239000011707 mineral Substances 0.000 abstract description 2
- 235000010755 mineral Nutrition 0.000 abstract description 2
- 230000001502 supplementing effect Effects 0.000 abstract description 2
- 206010016256 fatigue Diseases 0.000 description 73
- 238000012360 testing method Methods 0.000 description 24
- 241000893536 Epimedium Species 0.000 description 21
- 235000018905 epimedium Nutrition 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 18
- 241000133134 Saussurea Species 0.000 description 15
- 239000013642 negative control Substances 0.000 description 14
- 210000004185 liver Anatomy 0.000 description 12
- 230000009182 swimming Effects 0.000 description 11
- 229920002527 Glycogen Polymers 0.000 description 8
- 229940096919 glycogen Drugs 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 229930003944 flavone Natural products 0.000 description 7
- 235000011949 flavones Nutrition 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 150000002212 flavone derivatives Chemical class 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 5
- 239000004202 carbamide Substances 0.000 description 5
- 150000004676 glycans Chemical class 0.000 description 5
- 229920001282 polysaccharide Polymers 0.000 description 5
- 239000005017 polysaccharide Substances 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- QJVXKWHHAMZTBY-GCPOEHJPSA-N syringin Chemical compound COC1=CC(\C=C\CO)=CC(OC)=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 QJVXKWHHAMZTBY-GCPOEHJPSA-N 0.000 description 4
- QJVXKWHHAMZTBY-KSXIZUIISA-N syringin Natural products COc1cc(C=CCO)cc(OC)c1O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O QJVXKWHHAMZTBY-KSXIZUIISA-N 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 3
- TZJALUIVHRYQQB-XFDQAQKOSA-N Icariin Natural products O(C)c1ccc(C2=C(O[C@H]3[C@@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)C(=O)c3c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O4)c(C/C=C(\C)/C)c3O2)cc1 TZJALUIVHRYQQB-XFDQAQKOSA-N 0.000 description 3
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 3
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 238000000227 grinding Methods 0.000 description 3
- TZJALUIVHRYQQB-XLRXWWTNSA-N icariin Chemical compound C1=CC(OC)=CC=C1C1=C(O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)C(=O)C2=C(O)C=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-XLRXWWTNSA-N 0.000 description 3
- TZJALUIVHRYQQB-UHFFFAOYSA-N icariine Natural products C1=CC(OC)=CC=C1C1=C(OC2C(C(O)C(O)C(C)O2)O)C(=O)C2=C(O)C=C(OC3C(C(O)C(O)C(CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-UHFFFAOYSA-N 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000001243 protein synthesis Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 229930182490 saponin Natural products 0.000 description 3
- 150000007949 saponins Chemical class 0.000 description 3
- 235000017709 saponins Nutrition 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- 230000004584 weight gain Effects 0.000 description 3
- 235000019786 weight gain Nutrition 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 241001165494 Rhodiola Species 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- IRHTZOCLLONTOC-UHFFFAOYSA-N hexacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCO IRHTZOCLLONTOC-UHFFFAOYSA-N 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 2
- 150000002989 phenols Chemical class 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000018553 tannin Nutrition 0.000 description 2
- 239000001648 tannin Substances 0.000 description 2
- 229920001864 tannin Polymers 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 208000002381 Brain Hypoxia Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 241000283026 Cervus elaphus Species 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 235000017784 Mespilus germanica Nutrition 0.000 description 1
- 244000182216 Mimusops elengi Species 0.000 description 1
- 235000000560 Mimusops elengi Nutrition 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- ILRCGYURZSFMEG-UHFFFAOYSA-N Salidroside Natural products OC1C(O)C(O)C(CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-UHFFFAOYSA-N 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 235000007837 Vangueria infausta Nutrition 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000000386 athletic effect Effects 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000012156 elution solvent Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 239000005452 food preservative Substances 0.000 description 1
- 235000019249 food preservative Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 210000000607 neurosecretory system Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000036544 posture Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- ILRCGYURZSFMEG-RQICVUQASA-N salidroside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-RQICVUQASA-N 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
- A23P10/28—Tabletting; Making food bars by compression of a dry powdered mixture
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P20/00—Coating of foodstuffs; Coatings therefor; Making laminated, multi-layered, stuffed or hollow foodstuffs
- A23P20/10—Coating with edible coatings, e.g. with oils or fats
- A23P20/15—Apparatus or processes for coating with liquid or semi-liquid products
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/285—Aucklandia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/41—Crassulaceae (Stonecrop family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及保健食品技术领域,具体公开一种缓解体力疲劳的组合物及其制备方法。所述缓解体力疲劳的组合物包括:西洋参提取物5‑45份,淫羊藿提取物5‑45份,红景天提取物1‑35份和雪莲培养物1‑30份。本发明所提供的缓解体力疲劳的组合物采用五脏并补,以补心肺肾为主的用药特点,并辅以调节中枢神经系统,改善大脑的兴奋与抑制过程,增强机体免疫能力,从多方面来调节人体的内环境,达到改善血液循环,增加细胞携氧量,有效提高抗疲劳的效果。本组方在补充机体所需维生素、矿物质、蛋白质等基本营养素的前提下,从整体上调节人体内环境,扶助中气,协调脏腑经络机能,进而纠正阴阳偏盛偏衰,使机体恢复到阴平阳秘的正常状态。
Description
技术领域
本发明涉及保健食品技术领域,尤其涉及一种缓解体力疲劳的组合物及其制备方法。
背景技术
随着现代生活节奏的加快和工作压力的增加,疲劳在人群中的发生率越来越高,严重影响人们的生活质量和工作效率。慢性疲劳综合症(CFS)是介于健康与疾病的中间状态,仅是功能的紊乱,并不存在器质性病变,但若不及时纠正,将会逐渐积累,最终导致机体的神经、内分泌及免疫系统调节失常,甚至出现器质性病变,成为破坏人类身心健康的重要因素。由于现今社会工作任务繁重,各阶层的工作人员均出现了不同程度的慢性疲劳综合症,处于疲劳状态的人虽然能继续工作和学习,但是工作、学习能力和效率明显下降,且疲劳症状并不会因为休息而得到缓解。因此,疲劳被美国国家疾病控制和预防中心视为“21世纪人类的最大敌人”。
中医药在消除疲劳和增强运动能力方面有其独特的优势。现已证实,中医中药和食疗药物不仅可以增加人体内的能量物质,而且有调节神经内分泌系统、加强代谢等作用,并可刺激体内激素的分泌与释放,增强心血管系统、消化系统以及造血系统、骨骼系统等功能,延缓并消除过度疲劳的产生。目前,虽然现用于缓解体力疲劳的保健食品的种类繁多,但这些产品普遍存在成分复杂,效果不明显的缺陷,同时,由于成分复杂导致保健食品价格昂贵,无法长时间服用,不能达到持续、系统的缓解体力疲劳的效果。因此,研制一种成分简单、有效、可长期服用的缓解体力疲劳的保健食品具有十分重要的意义。
发明内容
针对现有技术中缓解体力疲劳的保健食品成分复杂,且抗疲劳效果不明显的技术问题,本发明提供一种缓解体力疲劳的组合物。
以及本发明还提供一种缓解体力疲劳的组合物的制备方法。
以及本发明还提供一种缓解体力疲劳的保健食品。
以及本发明还提供一种缓解体力疲劳片。
以及本发明还提供一种缓解体力疲劳片的制备方法。
为达到上述目的本发明实施例采用了如下的技术方案:
一种缓解体力疲劳的组合物,所述组合物包括如下重量份的组分:西洋参提取物5-45份,淫羊藿提取物5-45份,红景天提取物1-35份和雪莲培养物1-30份。
相对于现有技术,本发明根据疲劳形成的主要病因,选择西洋参、淫羊藿、红景天和雪莲培养物组成一个有机复方,采用五脏并补,以补心肺肾为主的用药特点,并辅以调节中枢神经系统,改善大脑的兴奋与抑制过程,增强机体免疫能力,从多方面来调节人体的内环境,达到改善血液循环,增加细胞携氧量,有效提高抗疲劳的效果。本组方在补充机体所需维生素、矿物质、蛋白质等基本营养素的前提下,从整体上调节人体内环境,扶正祛邪,扶助中气,协调脏腑经络机能,进而纠正阴阳偏盛偏衰,使机体恢复到阴平阳秘的正常状态。且本发明产品未使用任何食品防腐剂,安全可靠,适合长期食用。
西洋参性凉,性凉而补,入心肺肾三经,具有补肺降火,生津液,除烦倦等多重功效,其主要活性组分为西洋参皂苷,西洋参皂苷可以有效增强中枢神经功能,达到消除疲劳、增强记忆力等作用,同时西洋参还能强化心肌,增强心脏的活动能力,西洋参中含有的丰富的氨基酸、多糖、核酸、肽类、维生素和微量元素等还可以促进血清蛋白合成、骨髓蛋白合成、器官蛋白合成等,提高机体免疫力,增强体力,有效延缓疲劳的产生。
淫羊藿,味辛、甘,性温,走肝肾二经,含淫羊藿苷、多糖、挥发油、蜡醇、植物甾醇、鞣质、维生素E等成分,淫羊藿甙能增加心脑血管血流量,促进造血功能,增加脑血流量,改善微循环,对脑部缺血、缺氧具有明显的改善作用,从而可以有效缓解脑部疲劳;淫羊藿多糖具有促进机体免疫功能的作用,能够增加白细胞和淋巴细胞的数量,提高机体的免疫功能;且淫羊藿中还含有大量的黄酮,淫羊藿总黄酮具有延缓衰老的作用;此外,淫羊藿中含有丰富的Zn、Mn、Fe等微量元素以及生物碱等物质,还具有调节神经内分泌免疫的作用。本发明中西洋参中含有的西洋参多糖可以提高淫羊藿黄酮的生物活性,明显增强淫羊藿抗衰老的作用,进而可以显著延缓疲劳的产生。
红景天,性寒,其含有黄酮类、皂苷类、酚类、香豆素类、酶类和挥发油类等,此外红景天还含有18种氨基酸,35种微量元素及维生素A、C、D、E、B等。红景天苷可以通过调节毛细血管收缩而加快血液循环,提高对运动缺氧环境的适应性;红景天中含有的超氧化物歧化酶可提高机体的ATP含量,减少乳酸和丙酮的形成,增加肌酸磷酸激酶含量和改善血清总蛋白含量,从而使大量运动形成的疲劳得到显著改善;B族维生素能帮助蛋白质、脂肪和糖类被代谢利用,为大脑和身体提供能量,缓解疲劳感;除此之外,红景天中含有的多种氨基酸、维生素和丰富的钙、铁、锌等元素均能改善脑内神经突触部位的生理生化变化,为改善机体的疲劳状态提供多方面的功能协调。本发明中淫羊藿中含有的丰富的锌元素与红景天中的超氧化物歧化酶协同,可显著提高运动后中骨骼肌乳酸脱氢酶(LDH)的活性,促进LDH释放,加速分解乳酸和尿素氮,并其在过劳时,还能提高组织细胞对能量的利用率,加速疲劳的消除。
雪莲培养物,性大热,入肝脾肾三经,能补阴益阳,营养神经,含有丰富的黄酮类、多糖类、绿原酸、紫丁香苷和生物碱等活性物质,还含有18种氨基酸,且不仅含有与天然雪莲相近的活性成分,且亦具有与之相当的多方面的药理活性。雪莲培养物中的多糖对生物体内超氧阴离子自由基具有明显的清除作用,可延缓疲劳的产生;雪莲培养物中的总黄酮,具有免疫调节的作用,可增强机体的免疫力;雪莲培养物中还含有独特的黄硐类和雪莲内酯可有效清除氧自由基,防止染色体畸变,具有优异的防辐射能力;雪莲中含有的紫丁香苷可促进机体对淫羊藿、西洋参和红景天中活性组分的吸收利用,有效减少血尿素氮和乳酸的产生,提高机体承受运动负荷的能力,延缓疲劳的产生,加快疲劳的消除,进而提高三种组分的延缓疲劳出现以及加速疲劳消除的效果,且三种组分中含有的丰富的维生素E、及红景天含有的酚类、淫羊藿中的鞣质等能增强紫丁香苷在人体内的稳定性,进而保证了紫丁香苷对三种组分活性增强作用的发挥。
本发明中雪莲为大热物质,不适合阴虚火旺的人群长期服用,配以特定含量的红景天和西洋参,可调和雪莲的性热,使组方补而不燥,适合各种人群长期服用。本发明中西洋参、红景天和淫羊藿可加强雪莲培养物的益气补虚的功效,上四味药合用,补益肝心脾肺肾五脏,又可补气益精,缓解体力疲劳。
优选的,所述组合物包括如下重量份的组分:西洋参提取物20-30份,淫羊藿提取物20-30份,红景天提取物10-20份和雪莲培养物2-10份。
优选的,所述组合物包括如下重量份的组分:西洋参提取物25份,淫羊藿提取物25份,红景天提取物15份和雪莲培养物5份。
优选的,所述西洋参提取物和红景天提取物的制备方法为:
将西洋参和红景天根茎粉碎,得西洋参粗粉和红景天粗粉,分别向所述西洋参粗粉和红景天粗粉中加入其质量7-9倍的质量浓度为65-75%的乙醇溶液,加热回流提取1.5-2.5h,过滤,得第一滤渣和第一滤液;向所述第一滤渣中加入5-6倍量的质量浓度为65-75%的乙醇溶液,加热回流提取1.5-2.5h,过滤,得第二滤渣和第二滤液;向所述第二滤渣中加入5-6倍量的质量浓度为65-75%的乙醇溶液,加热回流提取1-2小时,过滤,得第三滤液,合并所述第一滤液、第二滤液和第三滤液,喷雾干燥,分别得到西洋参提取物和红景天提取物。
优选的,所述所述淫羊藿提取物的制备方法为:向淫羊藿中加入其质量9-11倍的质量浓度为65-75%的乙醇溶液,加热回流提取2-3次,每次提取时间为2-3h,过滤,得滤液,将所述滤液经填充大孔吸附树脂的层析柱进行洗脱,收集洗脱液,蒸发浓缩,喷雾干燥,得淫羊藿提取物。
西洋参、淫羊藿、红景天含有多种有效成分,如黄酮、总皂苷等,其具有显著的抗疲劳和使神经中枢兴奋的作用,采用上述制备方法可将西洋参、红景天和淫羊藿中的活性物质充分提取出来,从而提高本发明组合物的抗疲劳的作用。
优选的,步骤二中,所述大孔吸附树脂的型号为D101,洗脱溶剂为60-80%的乙醇溶液。
采用上述精制方法对淫羊藿提取物进行精制,可将提取物中大量的杂质去除,保证提取物中主要含有淫羊藿皂苷、黄酮等活性物质,从而提高提取物的抗疲劳的效果。
本发明还提供一种缓解体力疲劳的组合物的制备方法,至少包括以下步骤:
按照设计配比称取所述西洋参提取物、红景天提取物、淫羊藿提取物和雪莲培养物,混合均匀,得所述缓解体力疲劳的组合物。
本发明还提供一种缓解体力疲劳的保健食品,包括上述的缓解体力疲劳的组合物。
将缓解体力疲劳的组合物制成保健食品后,更适宜食用者服用和携带,便于长期食用,达到缓解体力疲劳的效果。
优选的,所述缓解体力疲劳的保健食品的剂型为粉剂、颗粒剂、胶囊剂或片剂。
本发明具有缓解体力疲劳的组合物在制备成保健食品时,除了包括有效的药物成分之外,还应包括制剂学上允许使用的载体如赋形剂和辅料。这些载体的作用是有助于有效成分加工成制剂,并且运载有效成分到体内作用部位。
本发明还提供一种缓解体力疲劳片,包括上述的缓解体力疲劳的组合物,还包括如下重量份数的原料:微晶纤维素10-40份,羧甲淀粉钠1-20份和硬脂酸镁1-2份。
本发明还提供一种缓解体力疲劳片的制备方法,至少包括以下步骤:
步骤a、按照设计配比称取所述西洋参提取物、红景天提取物、淫羊藿提取物、雪莲培养物和微晶纤维素,分别过筛,混合均匀,得预混物料;
步骤b,将所述预混物料过14-16目筛制粒,干燥,过14-16目筛整粒,得颗粒;
步骤c,向所述颗粒中加入所述羧甲淀粉钠和硬脂酸镁,混合均匀,得总混颗粒,将所述总混颗粒压片,得缓解体力疲劳片。
该制备方法工序通过混合、造粒、压片,使所得产品稳定性好,方便食用,且制备工艺无复杂工序,方法简单,适合工业化生产。
优选的,所述缓解体力疲劳片的制备方法还包括以下步骤:
步骤d,取薄膜包衣预混剂,用纯化水溶解,配制成固含量为18-22%的包衣液,将所述缓解体力疲劳片包衣,包衣至素片增重1.8-2.2%。
含有本发明缓解体力疲劳的片剂还可以包衣,以提供达到延长药效作用的剂型。
具体实施方式
为了使本发明的目的、技术方案及优点更加清楚明白,以下结合实施例,对本发明进行进一步详细说明。应当理解,此处所描述的具体实施例仅仅用以解释本发明,并不用于限定本发明。
实施例1
本发明实施例提供一种缓解体力疲劳片,所述缓解体力疲劳片包括如下重量份的组分:
西洋参提取物5份,淫羊藿提取物45份,红景天提取物1份,雪莲培养物30份,微晶纤维素40份,羧甲淀粉钠1份和硬脂酸镁1份。
上述缓解体力疲劳的片剂的制备步骤如下:
步骤一、将西洋参和红景天根茎粉碎,得西洋参粗粉和红景天粗粉,分别向所述西洋参粗粉和红景天粗粉中加入其质量8倍的质量浓度为70%的乙醇溶液,加热回流提取2.5h,过滤,得第一滤渣和第一滤液;向所述第一滤渣中加入5.5倍量的质量浓度为70%的乙醇溶液,加热回流提取2.5h,过滤,得第二滤渣和第二滤液;向所述第二滤渣中加入5.5倍量的质量浓度为70%的乙醇溶液,加热回流提取1小时,过滤,得第三滤液,合并所述第一滤液、第二滤液和第三滤液,喷雾干燥,分别得到西洋参提取物和红景天提取物;
步骤二、向淫羊藿中加入其质量11倍的质量浓度为65%的乙醇溶液,加热回流提取3次,每次提取时间为2h,过滤,得滤液,将所述滤液经填充大孔吸附树脂(D101)的层析柱,用80%的乙醇溶液洗脱,收集洗脱液,蒸发浓缩,喷雾干燥,得淫羊藿提取物;
步骤三、按照设计配比称取所述西洋参提取物、红景天提取物、淫羊藿提取物、雪莲培养物和微晶纤维素,分别过60目筛,混合均匀,得预混物料;
步骤四,将所述预混物料过16目筛制粒,干燥,过16目筛整粒,得颗粒;
步骤五,向所述颗粒中加入所述羧甲淀粉钠和硬脂酸镁,混合均匀,得总混颗粒,将所述总混颗粒压片,得缓解体力疲劳片。
本实施例制备的片剂片重0.55g,服用方法为每天一次,每次2片。
实施例2
本发明实施例提供一种缓解体力疲劳片,所述缓解体力疲劳片包括如下重量份的组分:
西洋参提取物45份,淫羊藿提取物5份,红景天提取物35份,雪莲培养物1份,微晶纤维素10份,羧甲淀粉钠20份和硬脂酸镁2份。
上述缓解体力疲劳的片剂的制备步骤如下:
步骤一、将西洋参和红景天根茎粉碎,得西洋参粗粉和红景天粗粉,分别向所述西洋参粗粉和红景天粗粉中加入其质量7倍的质量浓度为65%的乙醇溶液,加热回流提取2.5h,过滤,得第一滤渣和第一滤液;向所述第一滤渣中加入5倍量的质量浓度为65%的乙醇溶液,加热回流提取1.5h,过滤,得第二滤渣和第二滤液;向所述第二滤渣中加入5倍量的质量浓度为65%的乙醇溶液,加热回流提取2小时,过滤,得第三滤液,合并所述第一滤液、第二滤液和第三滤液,喷雾干燥,分别得到西洋参提取物和红景天提取物;
步骤二、向淫羊藿中加入其质量9倍的质量浓度为75%的乙醇溶液,加热回流提取2次,每次提取时间为3h,过滤,得滤液,将所述滤液经填充大孔吸附树脂(D101)的层析柱,用60%的乙醇溶液洗脱,收集洗脱液,蒸发浓缩,喷雾干燥,得淫羊藿提取物;
步骤三、按照设计配比称取所述西洋参提取物、红景天提取物、淫羊藿提取物、雪莲培养物和微晶纤维素,分别过60目筛,混合均匀,得预混物料;
步骤四,将所述预混物料过14目筛制粒,干燥,过14目筛整粒,得颗粒;
步骤五,向所述颗粒中加入所述羧甲淀粉钠和硬脂酸镁,混合均匀,得总混颗粒,将所述总混颗粒压片,得缓解体力疲劳片。
本实施例制备的片剂片重0.55g,服用方法为每天一次,每次2片。
实施例3
本发明实施例提供一种缓解体力疲劳片,所述缓解体力疲劳片包括如下重量份的组分:
西洋参提取物25份,淫羊藿提取物25份,红景天提取物15份,雪莲培养物5份,微晶纤维素20份,羧甲淀粉钠10份,硬脂酸镁1.5份和薄膜包衣预混剂2份。
上述缓解体力疲劳的片剂的制备步骤如下:
步骤一、将西洋参和红景天根茎粉碎,得西洋参粗粉和红景天粗粉,分别向所述西洋参粗粉和红景天粗粉中加入其质量9倍的质量浓度为75%的乙醇溶液,加热回流提取2h,过滤,得第一滤渣和第一滤液;向所述第一滤渣中加入6倍量的质量浓度为75%的乙醇溶液,加热回流提取2h,过滤,得第二滤渣和第二滤液;向所述第二滤渣中加入6倍量的质量浓度为75%的乙醇溶液,加热回流提取1.5小时,过滤,得第三滤液,合并所述第一滤液、第二滤液和第三滤液,喷雾干燥,分别得到西洋参提取物和红景天提取物;
步骤二、向淫羊藿中加入其质量10倍的质量浓度为70%的乙醇溶液,加热回流提取3次,每次提取时间为2.5h,过滤,得滤液,将所述滤液经填充大孔吸附树脂(D101)的层析柱,用70%的乙醇溶液洗脱,收集洗脱液,蒸发浓缩,喷雾干燥,得淫羊藿提取物;
步骤三、按照设计配比称取所述西洋参提取物、红景天提取物、淫羊藿提取物、雪莲培养物和微晶纤维素,分别过60目筛,混合均匀,得预混物料;
步骤四,将所述预混物料过16目筛制粒,干燥,过16目筛整粒,得颗粒;
步骤五,向所述颗粒中加入所述羧甲淀粉钠和硬脂酸镁,混合均匀,得总混颗粒,将所述总混颗粒压片,得素片;
步骤六:取薄膜包衣预混剂,用纯化水溶解,配制成固含量为20%的包衣液,将素片包衣,包衣至素片增重2%,得缓解体力疲劳片。
本实施例制备的片剂片重0.55g,服用方法为每天一次,每次2片。
本发明中缓解体力疲劳的组合物还可选择保健品领域常规的辅料按照常规的工艺制备为颗粒剂和胶囊剂。
缓解体力疲劳功能试验
试验对象:
本试验对象为雄性昆明种小鼠190只,体重18-22g,SPF级。
剂量设计:
将实施例3制备的缓解体力疲劳片设计为0.55g/Kg.BW,0.37g/Kg.BW,0.18g/Kg.BW三个剂量组,其剂量分别相当于人体推荐用量的30倍、20倍、10倍,另设计一个阴性对照组(蒸馏水)。
样品配制:分别称取实施例3制备的缓解体力疲劳片0.55g、0.37g、0.18g分别加蒸馏水至20mL,混合均匀,备用。
试验方法:
预游泳后选取姿势正确的雄性小鼠120只,分为3个试验组,每组用40只小鼠并随机分成4组,各试验组均设三个剂量组(1个中剂量组、1个高剂量组,1个低剂量组)和1个阴性对照组,每组10只。试验一组为负重游泳试验,试验二组为试验二组为血清尿素测定试验,试验三组为肝糖原测定试验,按上述剂量每天经口给予受试样品一次,阴性对照组给予等容量的蒸馏水,灌胃容量为20mL/Kg.BW,连续30天。
试验方法及结果:
1.负重游泳试验
末次给予受试物30min后,置小鼠在游泳箱中游泳,水深约35cm,水温(25土1)℃,鼠尾根部负荷5%体重的铅皮。记录小鼠自游泳开始至死亡时间,作为小鼠游泳时间(min)。死亡判断标准为:小鼠沉至游泳箱底并停止张口呼吸。并于试验开始之前和试验结束之后测量小鼠的体重。结果如表1所示。
表1
注:与阴性对照组比,**表示P<0.01。
由上述结果可以看出,各剂量组小鼠各期体重及增重与阴性对照组比较,均无显著性差异(P>0.05);各剂量组小鼠平均游泳时间较阴性对照组游泳时间均延长,且高剂量组与阴性对照组比较,有极显著性差异(P<0.01)。结果表明,该样品有延长小鼠负重游泳时间的作用。
2.血清尿素含量测定
末次给药30min后,小鼠在温度30℃的水中不负重游泳90min,休息60min后拔眼球采血0.5mL,分离血清后用全自动生化分析仪进行血清尿素测定。并于试验开始之前和试验结束之后测量小鼠的体重。结果如表2所示。
表2
注:与阴性对照组比,**表示P<0.01。
由上述结果可以看出,各剂量组小鼠各期体重及增重与阴性对照组比较,均无显著性差异(P>0.05);高剂量组小鼠血清尿素含量阴性对照组比较,有极显著性差异(P<0.01)。结果表明,该样品有减少疲劳小鼠尿素产生的作用。
3.肝糖原的测定
末次给药30min后,处死小鼠,解剖取肝脏,按试剂盒要求进行肝糖原含量测定。并于试验开始之前和试验结束之后测量小鼠的体重。结果如表3所示。
表3
注:与阴性对照组比,**表示P<0.01。
由上述结果可以看出,各剂量组小鼠各期体重及增重与阴性对照组比较,均无显著性差异(P>0.05);各剂量组小鼠肝糖原均高于阴性对照组,且高、中剂量组小鼠肝糖原含量阴性对照组比较,有极显著性差异(P<0.01)。结果表明,该样品可提高小鼠肝糖原储备量,提高小鼠耐力,缓解体力疲劳的发生。
实施例4
本发明实施例提供一种缓解体力疲劳片,所述缓解体力疲劳片包括如下重量份的组分:
西洋参提取物20份,淫羊藿提取物30份,红景天提取物10份,雪莲培养物10份,微晶纤维素10份,羧甲淀粉钠15份,硬脂酸镁2份和薄膜包衣预混剂2份。
上述缓解体力疲劳的片剂的制备方法与实施例3相同,此处不再赘述。
实施例5
本发明实施例提供一种缓解体力疲劳片,所述缓解体力疲劳片包括如下重量份的组分:
西洋参提取物30份,淫羊藿提取物20份,红景天提取物20份,雪莲培养物2份,微晶纤维素30份,羧甲淀粉钠3份,硬脂酸镁1份和薄膜包衣预混剂2份。
上述缓解体力疲劳的片剂的制备方法与实施例3相同,此处不再赘述。
对比例1
本对比例提供一种缓解体力疲劳片,原料按重量份数计包括如下组分:西洋参提取物25份,淫羊藿提取物25份,红景天提取物15份,马鹿茸5份,微晶纤维素20份,羧甲淀粉钠10份,硬脂酸镁1.5份和薄膜包衣预混剂2份。
对比例2
本对比例提供一种缓解体力疲劳片,原料按重量份数计包括如下组分:西洋参提取物25份,淫羊藿提取物25份,枸杞子10份,红景天提取物15份,雪莲培养物5份,微晶纤维素20份,羧甲淀粉钠10份,硬脂酸镁1.5份和薄膜包衣预混剂2份。
按照上述实施例3中的缓解体力疲劳试验的测试方法,测试实施例1-5及对比例1-2中缓解体力疲劳片的小鼠负重游泳时间、血清尿素氮和肝糖原,按照高剂量组的试验方法进行。将实施例1-5、阴性对照组、对比例1-2的测试结果汇总,如表4所示。
表4
以上所述仅为本发明的较佳实施例而已,并不用以限制本发明,凡在本发明的精神和原则之内所作的任何修改、等同替换或改进等,均应包括在本发明的保护范围之内。
Claims (10)
1.一种缓解体力疲劳的组合物,其特征在于,所述组合物包括如下重量份的组分:西洋参提取物5-45份,淫羊藿提取物5-45份,红景天提取物1-35份和雪莲培养物1-30份。
2.如权利要求1所述的缓解体力疲劳的组合物,其特征在于,所述组合物包括如下重量份的组分:西洋参提取物20-30份,淫羊藿提取物20-30份,红景天提取物10-20份和雪莲培养物2-10份。
3.如权利要求1所述缓解体力疲劳的组合物,其特征在于,所述组合物包括如下重量份的组分:西洋参提取物25份,淫羊藿提取物25份,红景天提取物15份和雪莲培养物5份。
4.如权利要求1-3任一项所述的缓解体力疲劳的组合物,其特征在于,所述西洋参提取物和红景天提取物的制备方法为:
将西洋参和红景天根茎粉碎,得西洋参粗粉和红景天粗粉,分别向所述西洋参粗粉和红景天粗粉中加入其质量7-9倍的质量浓度为65-75%的乙醇溶液,加热回流提取1.5-2.5h,过滤,得第一滤渣和第一滤液;向所述第一滤渣中加入5-6倍量的质量浓度为65-75%的乙醇溶液,加热回流提取1.5-2.5h,过滤,得第二滤渣和第二滤液;向所述第二滤渣中加入5-6倍量的质量浓度为65-75%的乙醇溶液,加热回流提取1-2小时,过滤,得第三滤液,合并所述第一滤液、第二滤液和第三滤液,喷雾干燥,分别得到西洋参提取物和红景天提取物。
5.如权利要求1-3任一项所述的缓解体力疲劳的组合物,其特征在于,所述淫羊藿提取物的制备方法为:向淫羊藿中加入其质量9-11倍的质量浓度为65-75%的乙醇溶液,加热回流提取2-3次,每次提取时间为2-3h,过滤,得滤液,将所述滤液经填充大孔吸附树脂的层析柱进行洗脱,收集洗脱液,蒸发浓缩,喷雾干燥,得淫羊藿提取物。
6.一种缓解体力疲劳的保健食品,其特征在于,包括权利要求1-5任一项所述的缓解体力疲劳的组合物。
7.如权利要求6所述的缓解体力疲劳的保健食品,其特征在于:其剂型为粉剂、颗粒剂、胶囊剂或片剂。
8.一种缓解体力疲劳片,其特征在于,所述缓解体力疲劳片包括权利要求1-5任一项所述的缓解体力疲劳的组合物,还包括如下重量份数的原料:微晶纤维素10-40份,羧甲淀粉钠1-20份和硬脂酸镁1-2份。
9.权利要求8所述的缓解体力疲劳片的制备方法,其特征在于,至少包括以下步骤:
步骤a、按照设计配比称取所述西洋参提取物、红景天提取物、淫羊藿提取物、雪莲培养物和微晶纤维素,分别过筛,混合均匀,得预混物料;
步骤b,将所述预混物料过14-16目筛制粒,干燥,过14-16目筛整粒,得颗粒;
步骤c,向所述颗粒中加入所述羧甲淀粉钠和硬脂酸镁,混合均匀,得总混颗粒,将所述总混颗粒压片,得缓解体力疲劳片。
10.如权利要求9所述的缓解体力疲劳片的制备方法,其特征在于,还包括以下步骤:
步骤d,取薄膜包衣预混剂,用纯化水溶解,配制成固含量为18-22%的包衣液,将所述缓解体力疲劳片包衣,包衣至素片增重1.8-2.2%。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910968586.3A CN110652006A (zh) | 2019-10-12 | 2019-10-12 | 一种缓解体力疲劳的组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910968586.3A CN110652006A (zh) | 2019-10-12 | 2019-10-12 | 一种缓解体力疲劳的组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110652006A true CN110652006A (zh) | 2020-01-07 |
Family
ID=69040628
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910968586.3A Pending CN110652006A (zh) | 2019-10-12 | 2019-10-12 | 一种缓解体力疲劳的组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110652006A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112655961A (zh) * | 2019-10-15 | 2021-04-16 | 神威药业集团有限公司 | 一种缓解体力疲劳的组合物 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103169079A (zh) * | 2013-03-04 | 2013-06-26 | 无锡市天赐康生物科技有限公司 | 一种具有抗疲劳、增强免疫力作用的保健食品及其制备方法 |
CN103750339A (zh) * | 2014-01-08 | 2014-04-30 | 大连普瑞康生物技术有限公司 | 雪莲培养物保健食品及其用途 |
CN105942521A (zh) * | 2016-05-09 | 2016-09-21 | 乌鲁木齐金骏阳光生物科技有限公司 | 含有肉苁蓉和淫羊藿提取物的组合物及其制备方法和应用 |
BG2526U1 (bg) * | 2016-11-24 | 2017-04-28 | Камелия Георгиева Цоклинова | Средство за повишаване на сексуалната активност |
CN107095304A (zh) * | 2017-07-12 | 2017-08-29 | 延边韩工坊健康制品有限公司 | 一种缓解体力疲劳保健食品及其制备方法 |
CN107281320A (zh) * | 2017-07-21 | 2017-10-24 | 安徽全康药业有限公司 | 一种能补肝肾、益精血、抗疲劳、防辐射中药组合物胶囊剂的制备方法 |
CN109077306A (zh) * | 2018-08-27 | 2018-12-25 | 辽宁众源生物科技有限公司 | 一种缓解疲劳的组合物及其制备方法 |
-
2019
- 2019-10-12 CN CN201910968586.3A patent/CN110652006A/zh active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103169079A (zh) * | 2013-03-04 | 2013-06-26 | 无锡市天赐康生物科技有限公司 | 一种具有抗疲劳、增强免疫力作用的保健食品及其制备方法 |
CN103750339A (zh) * | 2014-01-08 | 2014-04-30 | 大连普瑞康生物技术有限公司 | 雪莲培养物保健食品及其用途 |
CN105942521A (zh) * | 2016-05-09 | 2016-09-21 | 乌鲁木齐金骏阳光生物科技有限公司 | 含有肉苁蓉和淫羊藿提取物的组合物及其制备方法和应用 |
BG2526U1 (bg) * | 2016-11-24 | 2017-04-28 | Камелия Георгиева Цоклинова | Средство за повишаване на сексуалната активност |
CN107095304A (zh) * | 2017-07-12 | 2017-08-29 | 延边韩工坊健康制品有限公司 | 一种缓解体力疲劳保健食品及其制备方法 |
CN107281320A (zh) * | 2017-07-21 | 2017-10-24 | 安徽全康药业有限公司 | 一种能补肝肾、益精血、抗疲劳、防辐射中药组合物胶囊剂的制备方法 |
CN109077306A (zh) * | 2018-08-27 | 2018-12-25 | 辽宁众源生物科技有限公司 | 一种缓解疲劳的组合物及其制备方法 |
Non-Patent Citations (2)
Title |
---|
赖秋媛等: "中医药治疗运动性疲劳研究", 《新中医》 * |
陈晓霞等: "雪莲培养物保健品制备及其功效研究", 《科技创新导报》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112655961A (zh) * | 2019-10-15 | 2021-04-16 | 神威药业集团有限公司 | 一种缓解体力疲劳的组合物 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108434231B (zh) | 一种抗醉解酒的药食同源中药组合物及其制备方法 | |
KR20100127420A (ko) | 사포닌의 생체 이용률 증진 조성물 | |
CN102600212B (zh) | 一种增强免疫力、辅助治疗肿瘤的医药保健品 | |
CN102614499A (zh) | 一种具有抗疲劳功效的牦牛皮胶复方藏药及其制备工艺 | |
CN102907663A (zh) | 一种缓解体力疲劳的保健食品组合物及其制备方法 | |
CN105294811A (zh) | 以林芝灵芝为原材料制备林芝三萜酸及灵芝多糖的方法 | |
CN110664906B (zh) | 一种具有降血糖功能的保健食品的制备方法 | |
CN110652006A (zh) | 一种缓解体力疲劳的组合物及其制备方法 | |
CN110664860B (zh) | 一种增强免疫力的组合物及其制备方法 | |
CN102657730A (zh) | 一种抗高原反应的红景天口含剂 | |
CN112617196A (zh) | 一种抗缺氧、抗疲劳的食品、保健品或药物组合物及其制备方法和用途 | |
CN112655961A (zh) | 一种缓解体力疲劳的组合物 | |
CN106038702B (zh) | 抗疲劳的组合物及其制备方法和应用 | |
CN104922295A (zh) | 一种养血、补血的中药组合物 | |
CN104857180B (zh) | 抗疲劳及提高免疫力的组合物及其制备方法和应用 | |
CN106039172B (zh) | 含有积雪草的具有改善记忆功能的中药组合物及其应用 | |
CN115337350B (zh) | 一种具有强肾助阳作用的组合物制剂及其制备方法和应用 | |
CN113069505A (zh) | 一种提高免疫力的药膳饮品及其制备方法 | |
CN1150839C (zh) | 一种具有调节血压、调节血脂作用的保健食品及其制备方法 | |
CN1308009C (zh) | 具有调节血压功能的保健品 | |
CN102526370A (zh) | 提高人体免疫功能的虫草制剂及其制备方法 | |
CN1559523A (zh) | 脑得生软胶囊及其制备方法 | |
CN1686396A (zh) | 具有耐缺氧功能的保健品 | |
CN112655959A (zh) | 一种增强免疫力的组合物 | |
CN1686397A (zh) | 具有益肝功能的保健食品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200107 |
|
RJ01 | Rejection of invention patent application after publication |